Eli Lilly
-
Eli Lilly Invests $6 Billion in New Alabama Plant to Produce Active Pharmaceutical Ingredients
Eli Lilly will turn Huntsville, Alabama into the domestic hub for small‑molecule and peptide API production, investing more than $6 billion in a next‑generation facility that will manufacture its first oral GLP‑1 agonist, orforglipron. Construction begins in 2026, creating about 3,000 temporary jobs, and the plant—set to finish in 2032—will support 450 high‑skill positions. The site employs AI‑driven automation, aims for carbon‑neutral operations, and complements Lilly’s broader U.S. expansion to bolster supply‑chain resilience and domestic drug manufacturing.
-
.Lilly’s Jaypirca (pirtobrutinib) Achieves Primary Endpoint in Landmark Head‑to‑Head Phase 3 Trial Against Imbruvica (ibrutinib)
words.Eli Lilly’s Phase 3 BRUIN CLL‑314 trial showed pirtobrutinib, a reversible BTK inhibitor, achieved a non‑inferior ORR of 87 % versus 78.5 % for ibrutinib in CLL/SLL patients, meeting its primary endpoint. Early PFS trends favored pirtobrutinib, with a 43 % reduction in progression/death risk overall and 76 % in treatment‑naïve patients. The drug demonstrated a safer profile—lower atrial fibrillation (2.4 % vs. 13.5 %) and hypertension (10.6 % vs. 15.1 %). FDA‑approved after covalent BTK failure, it now seeks frontline indication, potentially reshaping the BTK inhibitor market.
